Amy T Peters1, Rachel H Jacobs1, Claudia Feldhaus1, David B Henry1, Anne Marie Albano2, Scott A Langenecker1, Mark A Reinecke3, Susan G Silva4, John F Curry5. 1. Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois. 2. Department of Psychiatry, New York State Psychiatric Institute, New York, New York. 3. Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 4. Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina. 5. Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina. Electronic address: john.curry@duke.edu.
Abstract
PURPOSE: It is well established that empirically supported treatments reduce depressive symptoms for most adolescents; however, it is not yet known whether these interventions lead to sustained improvements in global functioning. The goal of this study is to assess the clinical characteristics and trajectories of long-term psychosocial functioning among emerging adults who have experienced adolescent-onset major depressive disorder. METHODS:Global functioning was assessed using the Clinical Global Assessment Scale for children (participants ≤18 years), the Global Assessment of Functioning (participants ≥ 19 years) and the Health of the Nation Outcome Scales for Adolescents among 196 adolescents who elected to complete 3.5 years of naturalistic follow-up subsequent to their participation in the Treatment for Adolescents with Depression Study. The Treatment for Adolescents with Depression Study examined the efficacy of cognitive behavior therapy, fluoxetine, and the combination of cognitive behavior therapy and fluoxetine (combination treatment) over the course of 36 weeks. Mixed-effects regression models were used to identify trajectories and clinical predictors of functioning over the naturalistic follow-up. RESULTS:Global functioning and achievement of developmental milestones (college, employment) improved over the course of follow-up for most adolescents. Depressive relapse, initial randomization to the placebo group, and the presence of multiple psychiatric comorbidities conferred risk for relatively poorer functioning. CONCLUSIONS: Functioning generally improves among most adolescents who have received empirically supported treatments. However, the presence of recurrent major depressive disorder and multiple psychiatric comorbidities is associated with poorer functioning trajectories, offering targets for maintenance treatment or secondary prevention.
RCT Entities:
PURPOSE: It is well established that empirically supported treatments reduce depressive symptoms for most adolescents; however, it is not yet known whether these interventions lead to sustained improvements in global functioning. The goal of this study is to assess the clinical characteristics and trajectories of long-term psychosocial functioning among emerging adults who have experienced adolescent-onset major depressive disorder. METHODS: Global functioning was assessed using the Clinical Global Assessment Scale for children (participants ≤18 years), the Global Assessment of Functioning (participants ≥ 19 years) and the Health of the Nation Outcome Scales for Adolescents among 196 adolescents who elected to complete 3.5 years of naturalistic follow-up subsequent to their participation in the Treatment for Adolescents with Depression Study. The Treatment for Adolescents with Depression Study examined the efficacy of cognitive behavior therapy, fluoxetine, and the combination of cognitive behavior therapy and fluoxetine (combination treatment) over the course of 36 weeks. Mixed-effects regression models were used to identify trajectories and clinical predictors of functioning over the naturalistic follow-up. RESULTS: Global functioning and achievement of developmental milestones (college, employment) improved over the course of follow-up for most adolescents. Depressive relapse, initial randomization to the placebo group, and the presence of multiple psychiatric comorbidities conferred risk for relatively poorer functioning. CONCLUSIONS: Functioning generally improves among most adolescents who have received empirically supported treatments. However, the presence of recurrent major depressive disorder and multiple psychiatric comorbidities is associated with poorer functioning trajectories, offering targets for maintenance treatment or secondary prevention.
Authors: Benedetto Vitiello; Paul Rohde; Susan Silva; Karen Wells; Charles Casat; Bruce Waslick; Anne Simons; Mark Reinecke; Elizabeth Weller; Christopher Kratochvil; John Walkup; Sanjeev Pathak; Michele Robins; John March Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-12 Impact factor: 8.829
Authors: John Curry; Susan Silva; Paul Rohde; Golda Ginsburg; Betsy Kennard; Christopher Kratochvil; Anne Simons; Jerry Kirchner; Diane May; Taryn Mayes; Norah Feeny; Anne Marie Albano; Sarah Lavanier; Mark Reinecke; Rachel Jacobs; Emily Becker-Weidman; Elizabeth Weller; Graham Emslie; John Walkup; Elizabeth Kastelic; Barbara Burns; Karen Wells; John March Journal: J Consult Clin Psychol Date: 2012-01-16
Authors: James H Kocsis; Alan Schatzberg; A John Rush; Daniel N Klein; Robert Howland; Leah Gniwesch; Sonia M Davis; Wilma Harrison Journal: Arch Gen Psychiatry Date: 2002-08
Authors: Bruce F Chorpita; John R Weisz; Eric L Daleiden; Sonja K Schoenwald; Lawrence A Palinkas; Jeanne Miranda; Charmaine K Higa-McMillan; Brad J Nakamura; A Aukahi Austin; Cameo F Borntrager; Alyssa Ward; Karen C Wells; Robert D Gibbons Journal: J Consult Clin Psychol Date: 2013-08-26
Authors: Anna J Swan; Philip C Kendall; Thomas Olino; Golda Ginsburg; Courtney Keeton; Scott Compton; John Piacentini; Tara Peris; Dara Sakolsky; Boris Birmaher; Anne Marie Albano Journal: J Consult Clin Psychol Date: 2018-09
Authors: Claudia G Feldhaus; Rachel H Jacobs; Edward R Watkins; Amy T Peters; Katie Bessette; Scott A Langenecker Journal: J Child Fam Stud Date: 2020-04-28
Authors: Rachel H Jacobs; Edward R Watkins; Amy T Peters; Claudia G Feldhaus; Alyssa Barba; Julie Carbray; Scott A Langenecker Journal: PLoS One Date: 2016-11-23 Impact factor: 3.240
Authors: Katie L Bessette; Rachel H Jacobs; Charlotte Heleniak; Amy T Peters; Robert C Welsh; Edward R Watkins; Scott A Langenecker Journal: PLoS One Date: 2020-06-17 Impact factor: 3.240
Authors: Frank Iorfino; Daniel F Hermens; Shane Pm Cross; Natalia Zmicerevska; Alissa Nichles; Caro-Anne Badcock; Josine Groot; Elizabeth M Scott; Ian B Hickie Journal: BMJ Open Date: 2018-03-27 Impact factor: 2.692